Most women with advanced ovarian cancer will suffer a recurrence. There are many therapeutic options to consider at relapse, and it is the careful selection and use of chemotherapy and sometimes surgery that has over the last decade extended survival. Debulking surgery at relapse is currently ...
"Platinum resistant" ovarian cancer: What is it, who to treat and how to measure benefit? Platinum resistant ovarian cancer is comprised of a heterogeneous and complex spectrum of diseases.Detailing time to progression, method of determining pro... A Davis,AV Tinker,M Friedlander - 《Gynecologic...
Cervical cancer starts in the cells of the cervix. The cervix is the opening of the uterus.What increases my risk for cervical cancer?Human papillomavirus (HPV) infection Smoking cigarettes Age older than 60 Being overweight Use of certain hormone or fertility medicine A family history of ovarian...
8002 What is the best schedule of Topotecan? – weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer – a randomized, multicenter trial of the North-Eastern German Society of Gynaecological Oncology (TOWER) - ResearchGate DOI: 10.1016/S1359-6349(09)71524-1 被...
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tol... BACKGROUND: Recurrent platinum-resistant ovarian cancer usually has a poor outcome with conventional chemotherapeutic therapy and new treatment...
Act (ACA) coverage without their permission; Sen Elizabeth Warren (D, Massachusetts) said there are enough votes in the Senate to suspend the filibuster to codify Roe v Wade in 2025 with a Democratic majority; women with endometriosis have about a fourfold risk of deve...
8002 What is the best schedule of Topotecan? – weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer – a randomized, multicenter trial of the North-Eastern German Society of Gynaecological Oncology (TOWER) - ResearchGate...
F. Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening. J. Ovarian Res. 5, 30 (2012). Article CAS PubMed PubMed Central Google Scholar Carmody, L. C. et al. Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-...
PAX8 as a Target for Ovarian Cancer Therapy HGSC is still one of the most lethal malignancies that affect women worldwide because the majority of the cases are diagnosed after intraperitoneal spread, leading to a poor prognosis. Since PAX8 is expressed in Fallopian tube secretory cells and is ...
Last week, the FDA accepted a supplemental Biologics License Application (sBLA) from Genentech, granting its ovarian cancer drug Avastin priority review. The drug is intended to be taken in combination with chemotherapy for women suffering from recurrent platinum-resistant ovarian cancer. Avastin plus ...